Title:Fibroblast Growth Factor: Promising Target for Schizophrenia
Volume: 21
Issue: 13
Author(s): Ali Talaei, Tahereh Farkhondeh and Fatemeh Forouzanfar*
Affiliation:
- Neuroscience Research Center, Mashhad University of Medical Sciences, Mashhad,Iran
Keywords:
Fibroblast growth factors, dopamine, schizophrenia, psychosis, neurotrophic, antipsychotic drugs.
Abstract: Schizophrenia is one of the most debilitating mental disorders around the world. It is characterized
by neuroanatomical or biochemical changes. The role of the fibroblast growth factors (FGFs)
system in schizophrenia has received considerable attention in recent years. Various changes in the
gene expression and/or level of FGFs have been implicated in the etiology, symptoms and progression
of schizophrenia. For example, studies have substantiated an interaction between FGFs and the signaling
pathway of dopamine receptors. To understand the role of this system in schizophrenia, the databases
of Open Access Journals, Web of Science, PubMed (NLM), LISTA (EBSCO), and Google
Scholar with keywords including fibroblast growth factors, dopamine, schizophrenia, psychosis, along
with neurotrophic were searched. In conclusion, the FGF family represent molecular candidates as
new drug targets and treatment targets for schizophrenia.